What's the fda approval date for apotex's ruxolitinib?

Apotex’s generic version of ruxolitinib received FDA approval on August 30, 2022. The approval authorized the drug for the same indications as the original product (myelofibrosis, polycythemia vera, and related myeloproliferative neoplasms) and granted the generic a 30‑day period of marketing exclusivity.